Immune Modulation in Prostate Cancer Patients Treated with Androgen Receptor (AR)-Targeted Therapy.
abiraterone
androgen deprivation therapy
autoimmunity
enzalutamide
prognosis
prostate cancer
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
22 Jun 2020
22 Jun 2020
Historique:
received:
14
05
2020
revised:
12
06
2020
accepted:
19
06
2020
entrez:
26
6
2020
pubmed:
26
6
2020
medline:
26
6
2020
Statut:
epublish
Résumé
Androgen deprivation therapy (ADT) is a cornerstone of treatment for prostate cancer and, in recent years, androgen receptor (AR)-targeted therapies (abiraterone and enzalutamide) have both been used for the treatment of castration-resistant prostate cancer (CRPC). In our study, we sought to investigate the association between ADT and immune disorders, considering a potential role of androgens in the immune modulation. We retrospectively evaluated CRPC patients treated with abiraterone/enzalutamide between July 2011 and December 2018. We assessed the risk of developing immune alterations and their impact on outcome. We included 844 CRPC patients receiving AR-directed therapies, of whom 36 (4.3%) had autoimmune diseases and 47 (5.6%) second tumors as comorbidities. Median age was 70 years [interquartile range (IQR) = 63-75)]. We showed higher significant incidence of autoimmune diseases during their hormone sensitive status (
Identifiants
pubmed: 32580478
pii: jcm9061950
doi: 10.3390/jcm9061950
pmc: PMC7356925
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
N Engl J Med. 2013 Jan 10;368(2):138-48
pubmed: 23228172
J Natl Cancer Inst. 2010 Dec 1;102(23):1760-70
pubmed: 21068432
Eur Urol. 2019 Feb;75(2):319-328
pubmed: 30293908
Prostate Cancer Prostatic Dis. 2019 Sep;22(3):475-482
pubmed: 30692587
J Endocrinol. 2007 Mar;192(3):669-82
pubmed: 17332534
Front Pharmacol. 2016 Oct 13;7:376
pubmed: 27790145
Hum Immunol. 2010 May;71(5):496-504
pubmed: 20153396
Cancer Cell. 2005 Mar;7(3):239-49
pubmed: 15766662
Urol Oncol. 2018 May;36(5):240.e1-240.e11
pubmed: 29402534
J Intern Med. 2019 May;285(5):524-532
pubmed: 30873708
J Immunol. 2011 May 1;186(9):5162-72
pubmed: 21441459
Endocr Relat Cancer. 2017 Dec;24(12):T297-T310
pubmed: 28814451
Prostate. 2015 Sep;75(12):1329-38
pubmed: 25982919
Sci Transl Med. 2016 Apr 6;8(333):333ra47
pubmed: 27053771
Crit Rev Oncol Hematol. 2013 Apr;86(1):42-51
pubmed: 23092636
Urol Oncol. 2018 Nov;36(11):500.e11-500.e19
pubmed: 30249519
J Clin Oncol. 2016 Apr 20;34(12):1402-18
pubmed: 26903579
Cancer Res. 2012 Apr 15;72(8):1975-85
pubmed: 22374980
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
N Engl J Med. 2011 May 26;364(21):1995-2005
pubmed: 21612468
Biomed Pharmacother. 2014 Feb;68(1):21-4
pubmed: 24406295
N Engl J Med. 2014 Jul 31;371(5):424-33
pubmed: 24881730
PLoS One. 2016 Jul 19;11(7):e0158952
pubmed: 27434372
Cancers (Basel). 2017 Jan 27;9(2):
pubmed: 28134800
Biochem Pharmacol. 2019 Jul;165:196-206
pubmed: 30910694
Ann Oncol. 2018 Feb 1;29(2):386-391
pubmed: 29267861
Proc Natl Acad Sci U S A. 2014 Jul 8;111(27):9887-92
pubmed: 24958858
Pharmacol Res. 2018 Jul;133:277-288
pubmed: 29382608
N Engl J Med. 2012 Sep 27;367(13):1187-97
pubmed: 22894553
Eur Urol Focus. 2019 Mar;5(2):147-154
pubmed: 30772358
Cancer Immunol Res. 2015 Apr;3(4):345-55
pubmed: 25527358
Eur Urol Oncol. 2019 Feb;2(1):79-87
pubmed: 30929848
Int J Mol Sci. 2017 Dec 05;18(12):
pubmed: 29206214